Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Danny -

Devices aside, has the sentiment changed pertaining to Algernon's pipeline? Based on all your previous DD it seems we are still in good shape in that regard or is it your belief that is being spoonfed to us to further take investors for a ride?

No, my sentiment regarding the pipeline has not changed. However, my overall sentiment is one of urgency and survival. Please read the following 4 paragraphs from the AIF:

Excerpt from Page(s) 18 & 19

The Company is planning to conduct a minimum of two phase II clinical trials simultaneously in order to dramatically improve the Company’s potential of success. Since historically up to 50% of phase II trials achieve positive results and up to 33% of successful phase II drugs end up being approved, ensuring the Company is not conducting and relying on a single phase II clinical trial is key part of the current strategy.

Based on the success of the phase II trials, the Company plans to engage in licensing, partnership and or acquisition discussions (as the target) with a number of large pharmaceutical partners. If for whatever reason, a partnership, license or other does not materialize, the Company will explore moving all successful phase II compounds forward into phase III clinical trials.

At present, the Company does not plan to develop a sales team to advance the marketing sales and distribution of any of its lead compounds if such compounds achieve regulatory approval in any given market. The Company’s strategy is to look for moments of inflection where the potential exists to be able to consummate the best possible licensing or partnering deal or acquisition transaction.

The Company is also advancing the development of a POC breathalyzer device that could ultimately be instrumental in the research and development of regulatory approved test(s) that can screen or diagnose various human diseases using breath. The Company is not currently planning to advance this technology beyond the development of a working prototype but will look to license or pattern with a third party to advance the technology to the next development stage.

https://webfiles.thecse.com/sedar_filings/00037722/1904160953176150.pdf

Those 4 paragraphs is the entirety of whether or not we come away with a win or a total loss (as in the company is finished). Without a hit on one of at least two simultaneous trials we are done. Algernon will not get a do over beyond the initial trials coming out the gate. There simply is no money beyond this initial effort. We are positioned for a buyout target - that's the goal of management. Which brings me to the issue of the medical device. But for the medical device, none of us would be here. It's our company that Kal sold out to great profit to pursue other endeavors like Nash Pharmaceuticals. However, before Kal left us holding the bag, we were pitched the Nanose device in lieu of the FAIMS device as a distraction. The Nanose bombed out shortly after having paid 1M shares and 500K cash to Dr. Hossam Haick/Technion. It was a complete waste of shareholder time/money for a device that had already circled the globe and no one else bought into it but us. Meanwhile, Kal was setting up the pot stock pharma deal at Nash Pharmaceuticals. To my knowledge, Nash Pharma never had anything of value under it's belt - NADA. The plan to "acquire" Nash goes back at least to 2017 per a converstaion I had with Alfred Wong talking about a future acquisition at Breathtec. Although Wong would not tell me directly it was Nash Pharma, it became obvious to all prior to any announcement an acquisition of Nash Pharma was likely. Reason being, they werent doing jackshit at breathtec regarding ou tech. No news releases nothing for like 8 months! We didn't even have a CEO for a considerable length of time. A rudderless ghostship. In any event, Kal lucked up and leveraged a chance encounter between Chris Moreau and Dr. Mark Williams - Drug Repurposing strategy/research to put Nash Pharma in some type of legitimate status to ultimately take over Breathtec. Once Dr. Mark Williams was in place at Nash Pharma, Kal did a deal with himself to buy back Breathtec at the basement bargain price that he dumped it down to and subsequently abandoned. All of his conniving and manuevering revolves around the medical device. Which is/was the reason we were all here, and watched our money evaporate. Kal got everything he wanted out of Breathtec and spent nothing. The taking of half our share thereafter was Highway Robbery. Kal valued Bresthtec at less than half of Nash Pharmaceuticals - a company that had zero under it's belt prior to a chance conversation had between two friends (Chris & Mark). After the takeover of Breathtec was done, the stock subsequently tanked back to pre-split prices and worse. We never gained anything out the deal and forever lost half our equity in the company. Now we sit in an even riskier position. It's All or None now. Kal is a greedy human being. He has never done anything tangible for shareholder @ Breathtec. We have never ever seen a device. A device company/division without a device is a sham. So what I'm trying to get common shareholders to rally around is A LIFELINE. Meaning, if we are unsuccessful with trials and/or fail to get a serious cash upfront deal/partnership/buyout, where does it leave the medical device? The medical device plan in the AIF may not provide any tangible upfront cash or increased market cap. There's no timeline for when Yost will be done tinkering with a so called RUO device. So even pitching the device to another company for licensing or partnership simply is not relevant anymore. We don't have the luxury of Yost's infinite timeline or another company thereafter to walk a device through to commercialization. Such a del will most likely only benefit insiders (royalty fees). It's my belief THE ONLY WAY commoc shareholders can rightfully get what they deserve out of the complete fiasco Kal deliberately created at Breathtec is for Kal to man up and buyout our University of Florida Agreement. I mean seriously, Kal is the controlling interest of Cannabix and Algernon. Self dealing works well for Kal and pals. Chris Moreau was the CEO of both Breathtec and Nash Pharma at the time of the acquisition. Chris was effectively negotiating a buyout of Nash Pharma while sitting on both sides of the negotiating table. It's no wonder Nash Pharma was valued at more than Breathtec. Nash Pharma had more pals sitting on it's side of the "negotiating" table (Kal, Chris, Mark). This is all some crazy shit. So how about Kal do some crazy shit that actually takes care of those he's been shitting on for years. Buyout Algernon's medical side of the exact same technology @ Cannabix. Simply give us 1 Cannabix share for every 10 Algernon shares outstanding. That comes out to less than 5 Million USD for Cannabix to have it all. It gives Algernon shareholders a lifeline if Algernon goes bust. It's the right thing to do, but that's all the more reason why I believe Kal will not do it. Kal has proven himself to have no conscience.

GL2ALL

/////AMG